Bioequivalence To Duopa Could Mean Quick Path To Market For NeuroDerm In Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.